Tom joined Carisma Therapeutics in September 2019. He brings over 20 years of pharmaceutical and biotechnology industry experience, including corporate strategy, business development, R&D operations and marketing. Tom most recently served as the Chief Business Officer for LogicBio Therapeutics, Inc., a genome editing company, where he was responsible for leading strategy, business development and intellectual property, and supported a successful initial public offering. Prior to LogicBio, Tom was the Chief Business Officer for The University of Pennsylvania’s Gene Therapy Program, where he completed multiple partnerships that enabled the group to grow to over 250 employees. Tom began his career at GlaxoSmithKline, where he was instrumental in establishing the Rare Disease Business Unit and served in various leadership positions in the US and Europe.
Tom holds a BS from the University of London, an MA from the University of Leeds, and an MS from Brunel University.